In the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation
(ARISTOTLE) trial, apixaban is comparable to a vitamin K antagonist (VKA) in reducing …

Objective: To investigate the risk of bleeding events and stroke/systemic embolism (SE)
among Japanese patients with nonvalvular atrial fibrillation (NVAF), focusing on the initial …

Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to …

Purpose The aim of this study was to evaluate the cost-effectiveness of apixaban compared
with to warfarin, current standard of care, for stroke prevention in patients with nonvalvular …

Non‐vitamin K antagonists oral anticoagulants (NOACs) have recently challenged vitamin‐K
antagonists (VKAs) for stroke and systemic embolism prophylaxis in patients with non …

Oral anticoagulant therapy for stroke prevention in atrial fibrillation patients has been
remarkably changed by the introduction of non-vitamin k oral anticoagulants (NOAC) …

Introduction. Atrial fibrillation leads to increased risk of systemic embolism and stroke. To
decrease these adverse events, anticoagulation is routinely prescribed. Nonvitamin K …

Prior real-world studies have shown that apixaban is associated with a reduced risk of
stroke/systemic embolism (stroke/SE) and major bleeding versus warfarin. However, few …

Background Non-vitamin K antagonist oral anticoagulants (NOACs), including apixaban, are
recommended for prevention of stroke and systemic embolism in non-valvular atrial …

Background and Purpose—The use of oral anticoagulant therapy for stroke prevention in
atrial fibrillation has been transformed by the availability of the nonvitamin K antagonist oral …